GlassScriptPhysician profile
Duccio Baldari
NPI 1992786503
$156,649.08
in general payments reported to CMS, 2019-2025
60 companies · $3,682 in 2025
The $3,682 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $16K · 2021: $20K · 2022: $32K · 2023: $23K · 2024: $28K · 2025: $3,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $12K · Consulting Fee: $7,610 · Travel and Lodging: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,654.00 |
| Food and Beverage | $11,919.93 |
| Consulting Fee | $7,610.00 |
| Travel and Lodging | $937.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $129,524.24 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $4,993.95 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim International Gmbh | $2,960.00 | 2023 | Jardiance |
| Amgen INC. | $2,185.90 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,135.31 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $2,123.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,122.83 | 2019-2025 | Camzyos, Eliquis, Coumadin |
| Cvrx, INC. | $888.56 | 2023-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $856.75 | 2019-2020 | |
| Medtronic, INC. | $854.43 | 2021-2025 | Azure Xt Dr Mri Surescan, Symplicity G3, Protege Rx |
| Bard Peripheral Vascular, INC. | $684.63 | 2022-2025 | Venclose Maven Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $674.41 | 2021-2025 | |
| Abbott Laboratories | $606.52 | 2019-2025 | Amplatzer Amulet, Cardiomems, Nc Trek Neo |
| Pfizer INC. | $537.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $462.97 | 2021-2025 | Verquvo, Capvaxive |
Show all 54 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duccio Baldari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.